Navigating the 2026 Life Sciences Legal Landscape

Key themes evolving US Food and Drug Administration (FDA) oversight, enforcement and litigation activity, drug pricing and market access, and intellectual property strategy pressures. These developments carry significant near-term operational, litigation, pricing, and compliance implications that warrant proactive planning across portfolios and with trading partners.

1. Medicare Drug Price Negotiation Expansion and Implementation

The first round of negotiated drug prices under the Medicare Drug Price Negotiation Program took effect on January 1, applying to 10 Part D drugs including Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and NovoLog. These negotiated prices represent discounts of at least 38% off 2023 list prices and are estimated to save the Medicare program $6 billion annually. The second negotiation cycle has selected 15 additional drugs, including the blockbuster GLP-1 medications Ozempic and Wegovy, with negotiated prices taking effect January 1, 2027. The Trump Administration has indicated it will maintain the program while seeking “room for improvement,” including addressing the “pill penalty” that subjects small molecule drugs to earlier negotiation eligibility than biologics. Life sciences companies should prepare for continued program expansion, with up to 15 drugs selected for 2028 and 20 drugs annually thereafter, and should evaluate how negotiated prices may affect pricing strategies across their portfolios.

2. Continued Antitrust Scrutiny of Life Sciences M&A

Life sciences transactions remain a central enforcement priority for the Federal Trade Commission (FTC) and US Department of Justice (DOJ) under both Democratic and Republican Administrations. The FTC challenged two life sciences transactions in 2025 — GTCR’s proposed acquisition of Surmodics and Edwards Lifesciences’ proposed acquisition of JenaValve — underscoring the agency’s continued focus on medical device transactions. Both agencies have retained the 2023 Merger Guidelines, which lower thresholds for presumptive illegality and expand the range of competitive harms considered. However, the new Administration has re-embraced negotiated remedies, enabling greater flexibility for deal clearance through divestitures. In Europe, regulators continue efforts to expand jurisdiction over “killer acquisitions” of pipeline assets, with the Lear report suggesting that Article 101 and 102 antitrust tools could address problematic deals falling outside merger control. Companies contemplating transactions should anticipate that factors increasing scrutiny include the presence of active complainants, pipeline overlaps, and concerning internal documents.

3. Record-Breaking False Claims Act Enforcement

Fiscal year 2025 shattered False Claims Act (FCA) records, with settlements and judgments exceeding $6.8 billion — the highest annual total in the statute’s history. Health care-related matters accounted for over $5.7 billion (83%) of total recoveries. Whistleblower qui tam lawsuits reached 1,297 new filings, the highest ever in a single year. Notably, for the first time, more funds were recovered in health care FCA cases where the government declined to intervene ($2.27 billion) than in cases it joined ($2.23 billion), signaling that relator-driven litigation remains a significant threat even without DOJ participation. Key enforcement priorities include managed care and Medicare Advantage risk adjustment, prescription drug pricing and kickbacks, cybersecurity compliance, and expanding theories involving digital health and diversity, equity, and inclusion initiatives. The DOJ’s creation of the Division for National Fraud Enforcement in January 2026 signals continued aggressive use of the FCA.

4. Anti-Kickback and PBM Enforcement Intensification

The FTC continues to scrutinize pharmacy benefit manager (PBM) conduct, with concerns that exclusionary rebate arrangements and formulary steering may constitute unfair methods of competition. In September 2024, the FTC brought action against the three largest PBMs for engaging in anticompetitive rebating practices alleged to have artificially inflated insulin prices. The FTC’s Second Interim Staff Report in January 2025 found that the “Big 3” PBMs imposed significant markups on specialty generics, and panelists at subsequent listening sessions criticized PBM practices as having “significant negative impact on the biosimilars industry.” Life sciences companies face continued enforcement against speaker programs, with Gilead Sciences agreeing to pay $176 million to resolve allegations of paying high-volume prescribers hundreds of thousands in honoraria to promote HIV drugs. Patient support program structures also remain under scrutiny, with QOL Medical paying $47 million to resolve allegations that free breath testing constituted unlawful inducements.

5. Biosimilar Patent Litigation and BPCIA Developments

The biosimilar market continues to evolve with specialized patent litigation procedures under the Biologics Price Competition and Innovation Act (BPCIA), including the “patent dance” framework for pre-litigation information exchange. The US Supreme Court’s Sandoz v. Amgen decision confirmed the patent dance’s optionality, allowing biosimilar applicants to skip the information exchange and inviting litigation uncertainty. Recent data shows biosimilar challengers achieving success in invalidating at least one patent claim in 70% of instituted inter partes review proceedings at the Patent Trial and Appeal Board, with the Board demonstrating a 73% institution rate for bio and pharma petitions. Biosimilar litigation settlement remains the most common outcome, with 75% of cases resolved through settlement. A troubling “biosimilar void” has emerged: Of 118 biologics expected to lose patent protection between 2025 and 2034, 90% have no publicly disclosed biosimilars in development, attributed to high development costs, lengthy timelines, and patent thicket litigation expenses.

6. FDA QMSR Alignment

In 2026, the FDA updated its rules under the Quality Management System Regulation (QMSR), aligning US quality requirements with international standards. Manufacturers of medical devices, including those with artificial intelligence (AI) capabilities, must meet updated baseline quality requirements that require companies to design safe products, manage risk, and document updates. This regulatory harmonization affects life sciences companies with international operations and those seeking to streamline global compliance programs. Companies should assess current quality systems against the updated QMSR requirements and develop implementation plans to ensure compliance with the new framework.

7. Heightened Hatch-Waxman and Generic Drug Litigation Activity

The Hatch-Waxman framework continues to generate significant patent litigation, with the 30-month stay and 180-day exclusivity period remaining critical strategic elements for both brand and generic companies. Paragraph IV certifications triggering patent infringement lawsuits remain the primary mechanism for generic market entry. The FTC continues to scrutinize Orange Book listings, with the Trump FTC announcing renewed challenges against “improperly listed device patents” and sending warning letters to pharmaceutical companies regarding 17 brand-name products. Pay-for-delay arrangements remain a key enforcement priority, with staff commentary flagging that quantity restrictions and non-cash settlement structures may qualify as unlawful reverse payments. Product-hopping and exclusive distribution restrictions are similarly under scrutiny. The First Circuit’s February 2025 decision in Regeneron Pharmaceuticals adopted the more stringent but-for causation standard for Anti-Kickback Statute violations giving rise to FCA liability, creating a circuit split likely headed for Supreme Court resolution.

8. USPTO Patent Prosecution Changes and Fee Increases Affecting Life Sciences

Significant changes at the US Patent and Trademark Office (USPTO) in 2025 and 2026 are reshaping patent prosecution strategy for life sciences companies. New fee structures took effect January 19, 2025, including a 7.5% across-the-board increase plus an additional 2.5% boost to front-end fees. The USPTO also implemented surcharges on continuation applications based on how long after the earliest priority date they are filed — $2,700 for applications filed six to nine years after the earliest priority date and $4,000 for those filed more than nine years after the earliest priority date. Patent term extension application fees increased to $2,500, and a new $1,440 fee applies when applicants file terminal disclaimers after receiving a Notice of Final Determination. These continuation surcharges particularly affect life sciences companies that rely on continuation strategies to protect evolving product portfolios over lengthy drug development timelines. The USPTO also discontinued the Accelerated Examination program for utility applications as of July 10, 2025, though Track One prioritized examination remains available. As noted above, the FTC continues to aggressively challenge allegedly improper Orange Book patent listings, issuing renewed warning letters in May 2025 disputing more than 200 patents across 17 brand-name products — the agency’s first round under the Trump Administration. Following the Federal Circuit’s December 2024 decision in Teva v. Amneal, which held that device patents for drug delivery components do not qualify for Orange Book listing, companies should carefully evaluate whether their existing listings meet statutory requirements. Failure to do so may invite antitrust scrutiny and delisting orders.

9. FDA Sweep of Deceptive DTC Ads – Especially on Social Media 

The US Department of Health and Human Services (HHS) and FDA announced a nationwide crackdown on misleading direct-to-consumer (DTC) drug ads, issuing thousands of letters and approximately 100 warning and untitled letters to pharmaceutical manufacturers. The FDA additionally noted that it has begun using AI-enabled tools to proactively monitor for violative content. Expect heightened risk for social media and influencer campaigns that lack fair balance. Audit pipelines now and remediate risk disclosures and social media/influencer practices.

10. Federal Court Halts 340B Rebate Model Pilot Program 

On December 29, 2025, a federal court in Maine issued a preliminary injunction temporarily blocking the Health Resources and Services Administration’s (HRSA) 340B Rebate Model Pilot Program just four days before its January 1, 2026, effective date. The pilot would have required covered entities to purchase qualifying drugs at commercial prices and then submit data to manufacturers to receive post-purchase rebates reflecting the difference between the purchase price and the 340B price. The court found the administrative record “anemic” and held that the plaintiffs showed a strong likelihood of success on their claim that HRSA violated the Administrative Procedure Act’s arbitrary and capricious standard by failing to consider the covered entities’ 30-year reliance on upfront discounts and by inadequately evaluating administrative costs. HRSA immediately appealed, but the First Circuit declined to stay the injunction and HHS dismissed the appeal. Then, on February 5, 2026, the parties in the district court case filed a joint motion to vacate the case. Now, the Administration has signaled it will engage in additional rulemaking to again propose a new rebate model. Stay tuned.

11. FDA Warning Letters Fuel Consumer Class Actions Against Digital Health Companies

A putative class action against Whoop demonstrates how FDA enforcement can rapidly cascade into consumer litigation. In Rowe v. Whoop, Inc., No. 3:25-cv-09910 (N.D. Cal. Nov. 18, 2025), the plaintiff uses the FDA’s July 2025 warning letter regarding Whoop’s Blood Pressure Insights (BPI) feature as the foundation for claims under California’s Unfair Competition Law, False Advertising Law, and Consumer Legal Remedies Act. The FDA concluded that the BPI feature constitutes a medical device based on its intended use, design, and marketing, and that the product is adulterated for lack of premarket authorization and misbranded for lack of premarket notification. The FDA rejected Whoop’s argument that the feature qualifies for the “wellness exception” under the 21st Century Cures Act, finding that blood-pressure estimation is not low-risk because inaccurate outputs can falsely reassure hypertensive users or delay care. The plaintiff seeks damages on the theory that consumers paid premium prices for features that were not legally marketed. The case signals that when a feature falls within a category the FDA has long regulated, wellness branding will not sidestep device requirements — and FDA enforcement may expose companies to downstream consumer protection claims. The case highlights that as the next wave of wearables and longevity tech pushes deeper into metabolic, cardiovascular, and recovery optimization, product characterization from an FDA standpoint becomes paramount. 

12. FDA Issues First DSCSA Form 483 to a Dispenser, Signaling Active Enforcement

The FDA issued a Form 483 to a Texas med spa, Pure Indulgence Aesthetics, citing Drug Supply Chain Security Act (DSCSA) violations — the first DSCSA-focused 483 issued to a dispenser based on publicly available records. The FDA inspected the facility between December 2 and December 12, 2025, just days after the dispenser exemption stabilization period ended on November 27, 2025. The inspection focused on Botox, and the FDA cited two violations under section 582(d) of the Federal Food, Drug, and Cosmetic Act: failure to conduct business only with authorized trading partners and failure to transact only in product with a product identifier. Investigators compared manufacturer shipment records with patient treatment records and determined that units dispensed significantly exceeded units purchased from authorized sources, strongly suggesting product was obtained from unauthorized trading partners. The 483 underscores that dispensers’ baseline DSCSA obligations are fully in force and fair game for enforcement, independent of enhanced electronic interoperability requirements. Life sciences companies should note that the FDA can leverage data sources already abundant in clinical settings, comparing manufacturer shipment records with treatment logs to prove violations.

13. Longevity Emerges as a Strategic Frontier for Life Sciences

Longevity and healthspan innovation have moved from the margins of wellness into the strategic core of the life sciences sector. Biopharmaceutical companies, diagnostics developers, device manufacturers, and research platforms are increasingly pursuing interventions that target biological aging, functional decline, and chronic disease risk, reshaping pipelines, partnerships, and investment priorities across senolytics, metabolic therapeutics, biomarker-driven diagnostics, and digitally enabled preventive care. For many life sciences companies, longevity is no longer a peripheral opportunity, but a platform strategy influencing research and development, clinical trial design, and commercialization pathways.

This shift requires navigating a layered legal and regulatory landscape. Existing FDA frameworks remain organized around discrete disease indications rather than aging biology, though recent developments, such as the agency’s clearance of a Phase 1 clinical trial by Life Biosciences targeting aging-related biology in ocular tissues, signal growing openness to pathway-based approaches. Beyond FDA oversight, longevity’s intersection with clinical care, consumer health platforms, and AI implicates corporate practice of medicine, licensure, reimbursement, FTC enforcement, and data privacy considerations. Marketing communications face particular scrutiny where statements about aging-related outcomes risk being construed as efficacy claims. As capital flows into space, life sciences companies will need coordinated regulatory, privacy, and transactional strategies to navigate these multi-faceted issues.